YM 57158

Drug Profile

YM 57158

Alternative Names: YM 158

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antiasthmatics
  • Mechanism of Action Leukotriene D4 receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic rhinitis; Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Allergic-rhinitis in Europe (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in Europe (PO)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top